Stocktoria
Stereotaxis, Inc. STXS
NYSE American · XASE · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2004-08-12
Stereotaxis, Inc. (STXS) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $32.4M at a -66.8% net margin.
Chart by TradingView
4/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Price from month-end closes (Yahoo) — for reference, not real-time.
Revenue trend · last 10y · up
How it ranks in Manufacturing · percentile among 1829 companies
Piotroski Fstronger than 44%
Net marginstronger than 24%
Return on equitystronger than 11%
Revenue growthstronger than 80%
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Detailed pages
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| STXS | Stereotaxis, Inc. | 4/9 | — | — | +20.3% |
| ECOR | electroCore, Inc. | 4/9 | — | — | +27.2% |
| POCI | PRECISION OPTICS CORPORATION, INC. | 3/9 | -8.27 | — | -0.1% |
| QTI | QT IMAGING HOLDINGS, INC. | 5/9 | -4.34 | — | — |
| HYPR | Hyperfine, Inc. | 4/9 | -16.31 | — | +5.2% |
| CV | CapsoVision, Inc | 2/9 | — | — | +15.3% |
| IRIX | IRIDEX CORP | 4/9 | -8.01 | — | +8.2% |
FAQ
Is STXS financially healthy?
Stereotaxis, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does STXS pay a dividend?
No, Stereotaxis, Inc. does not currently pay a dividend.
How profitable is STXS?
In FY2025, Stereotaxis, Inc. had a net margin of -66.8% and a return on equity of -160.5%.
Source: SEC EDGAR filings · CIK 0001289340 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.